Avacta Group plc (LON:AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISIONTM platforms, has announced significant progress in the development of a highly scalable manufacturing process for

Avacta is supporting global efforts in combating the COVID-19 pandemic by using its Affimer®  platform to develop diagnostic reagents for COVID-19 ANTIGEN testing. Avacta has generated a large number of

Cytiva launches new services for diagnostic developers and will establish new labs to meet the future needs of the industry. Cytiva Diagnostic Services will help developers bring point-of-care diagnostic tests to market quicker

The Wetherby-based firm hopes to get the test, which works like a pregnancy test but uses saliva, validated before the end of 2020, which could be a game changer for

Wouldn’t it be great to have a test for Covid-19 that’s as simple as a home pregnancy kit?  Instead of weeing on it, you spit and it gives you an

Avacta said is continuing to work with the UK government’s CONDOR programme to obtain regulatory approval in the UK to use the test for diagnostic purposes too. The bead-assisted mass spectrometry (‘BAMS’)

Avacta Group’s CEO predicts a “transformational year” ahead with “momentous milestones” for the company as it progresses its Covid-19 test and other products. The Whittlesford-based drug development company unveiled interim